{"page_content": "9Number Disclosure Reported Response\n1.1 Statement from CEO environment.amgen.com (Leadership Message)Report Parameters (continued)\nNumber Disclosure Reported Response\n3.7 Limitations on the scope and boundary of the reportItems that are out of scope for this report include global sales and \nadministrative offices with minimal environmental impact; outsourced activities, such as contract manufacturers; Onyx Pharmaceuticals,  which was acquired in 2013; companies acquired in 2012, including Micromet, KAI Pharmaceuticals, deCODE genetics, and Mustafa Nevzat Pharmaceuticals; and Amgen\u2019s facility in S\u00e3o Paulo, Brazil, acquired in 2011.\n3.8 Basis for reporting\nThe in-scope facilities listed in indicator 3.6 represent our 15 manufacturing, research and development, and distribution facilities in North America, Europe, and Puerto Rico. These facilities represent 94 percent of our operations, based on the square footage of our facilities. The remaining square footage primarily includes administrative offices. We do not include environmental data from outsourced activities in this report.\n3.9 Data measurement techniques and bases of calculations and assumptions\nenvironment.amgen.com (Summary of Data Notes)\n3.10 Explanation of the effect of any restatements No restatements\n3.11 Significant changes from previous reporting periodsIn 2013, Amgen acquired one company: Onyx Pharmaceuticals. For the 2013 report, data from this company will not be included.\n3.12 GRI content index table\nenvironment.amgen.com (GRI Index)\nGovernance, Commitments, and Engagement\nNumber Disclosure Reported Response\n4.1 Governance structure including committeesenvironment.amgen.com (Governance) \nwww.amgen.com (Corporate Governance)\n4.2 Indicate whether the chair of the highest governance body is also an executive officerRobert Bradway is both CEO and Chairman of the Board. For more \ninformation on Amgen\u2019s Board, see amgen.com (Corporate Governance) \n4.3 Unitary board structure www.amgen.com (Corporate Governance)\n4.4Mechanisms for shareholders and employees to provide recommendations/direction to highest governance boardwww.amgen.com (Corporate Governance)\n4.14 List of stakeholder groups engaged by the organization environment.amgen.com (Stakeholder Engagement)\n4.15 Basis for identification and selection of stakeholders with whom to engage environment.amgen.com (Stakeholder Engagement)\nEconomic Performance Indicators\nNumber Disclosure Reported Response\nEC1 Economic Performance: Direct economic value generated and distributedenvironment.amgen.com (Summary of Data and Data Notes)\nwww.amgen.com (2013 Annual Report and Financial Summary)\nEC2Economic Performance: Financial implications and other risks and opportunities due to climate changeWe\u2019re actively working to conserve energy and reduce greenhouse gas emissions that result from our operations. We have also considered potential risks to our business associated with climate change such as extreme weather events and increasing regulation. Financial impact is considered as part of our risk management processes. Having plans in place to mitigate these risks increases the overall sustainability of the business.\nEC9Indirect Economic Impacts: Understanding and describing significant indirect economic impacts, including the extent of impacts\nwww.amgen.com (AmgenAssist)GRI Index\nReported Partial", "metadata": {"source": "NASDAQ_AMGN_2013.pdf", "page": 8, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}